



Correction to: Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: results of a single-center, multi-arm phase Ib study

Kyaw Z. Thein^{1,2} · Daniel D. Karp¹ · Apostolia Tsimberidou¹ · Jing Gong¹ · Selma Sulovic¹ · Jatin Shah³ · Denái R. Milton⁴ · David S. Hong¹ · Filip Janku¹ · Lacey McQuinn¹ · Bettzy A. Stephen¹ · Rivka Colen⁵ · Brett W. Carter⁶ · Timothy A. Yap¹ · Sarina A. Piha-Paul¹ · Siqing Fu¹ · Funda Meric-Bernstam¹ · Aung Naing^{1,6}

Published online: 3 November 2021
© The Author(s) 2021

Correction to: Investigational New Drugs
<https://doi.org/10.1007/s10637-021-01188-1>

The article **Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: Results of a single-center, multi-arm phase Ib study** was originally published electronically on the publisher's internet portal on 25 September 2021 without open access. The author decided to opt for Open Choice and to make the article an Open Access publication. Therefore, the copyright of the article has been changed to © The Author(s) 2021 and the article is forthwith distributed under a Creative Commons Attribution 4.0 International License (<https://creativecommons.org/licenses/by/4.0/>), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the origi-

nal author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.

The original article has been corrected.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

The original article can be found online at <https://doi.org/10.1007/s10637-021-01188-1>.

✉ Kyaw Z. Thein
theink@ohsu.edu

¹ Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

² Division of Hematology and Medical Oncology, Oregon Health and Science University/ Knight Cancer Institute, Portland, OR, USA

³ Karyopharm Therapeutics, Newton, MA, USA

⁴ Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

⁵ Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

⁶ Department of Thoracic Imaging, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.